Collectively, our results show that independent of tissue niche, tumor-intrinsic ATG16L1 profoundly limits immune-mediated control of CRC, whereas it has a relatively minor impact when tumors are grown in immunodeficient hosts. Here, ATG16L1 is linked to colorectal carcinoma.